Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide

  • Melissa Rayburg
  • , Alexander Towbin
  • , Hong Yin
  • , Todd Maugans
  • , Barry Maurer
  • , Rajaram Nagarajan
  • , Brian Weiss

Research output: Contribution to journalArticlepeer-review

Abstract

Langerhans cell histiocytosis (LCH) has previously been reported in association with other malignancies. The pathogenesis of LCH and its relationship to other malignancies is poorly understood. We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym-X-Sorb (4-HPR/LXS) powder for neuroblastoma.

Original languageEnglish (US)
Pages (from-to)1111-1113
Number of pages3
JournalPediatric Blood and Cancer
Volume53
Issue number6
DOIs
StatePublished - 2009
Externally publishedYes

Keywords

  • Fenretinide
  • LCH
  • Neuroblastoma
  • New agents
  • Pediatric oncology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide'. Together they form a unique fingerprint.

Cite this